Evidence map›Paper›PMID 39083120›Full record

ArticleSurgery today2025

The KRAS G12D mutation increases the risk of unresectable recurrence of resectable colorectal liver-only metastasis.

Kai Chen, Yukiyasu Okamura, Keiichi Hatakeyama, Akio Shiomi, Hiroyasu Kagawa, Hitoshi Hino, Shoichi Manabe, Yusuke Yamaoka, Teiichi Sugiura, Takashi Sugino and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kai ChenDivision of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Yukiyasu OkamuraDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan. okamura.yukiyasu@nihon-u.ac.jp.ORCID http://orcid.org/0000-0003-3384-2709
Keiichi HatakeyamaCancer Multiomics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Akio ShiomiDivision of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Hiroyasu KagawaDivision of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Hitoshi HinoDivision of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Shoichi ManabeDivision of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Yusuke YamaokaDivision of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Teiichi SugiuraDivision of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Takashi SuginoDivisions of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Akifumi NotsuClinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
Takeshi NagashimaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Keiichi OhshimaMedical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Kenichi UrakamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yasuto AkiyamaImmunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Ken YamaguchiShizuoka Cancer Center, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUnresectable recurrence is a critical predictor of outcomes for colorectal cancer patients. We attempted to identify the prognostic factors, especially for unresectable recurrence-free survival (URFS) as a new endpoint, in patients with resectable colorectal liver-only metastasis (CRLOM).

methodsWe investigated patients with resectable CRLOM, who underwent an R0 resection for both CRC and CRLOM between January, 2014 and March, 2019 at a single institution. The exclusion criteria were patients who received neoadjuvant treatment, the absence of data for genetic analyses, and the presence of multiple cancers, synchronous CRC, or familial adenomatous polyposis. The prognostic factors were examined retrospectively using data on pre-hepatectomy factors, including primary tumor molecular profiling results.

resultsWe analyzed the data of 101 patients who underwent curative-intent surgery for CRLOM. Multivariate analysis revealed that KRAS G12D mutation-positivity (hazard ratio [HR]: 7.69; p < 0.01), RYR2 mutation-positivity (HR: 4.03; p < 0.01), and KRAS G12S mutation-positivity (HR: 3.96; p = 0.03), CA19-9 > 37 U/ml before hepatectomy (HR: 3.62; p < 0.01), and primary tumor pN2 stage (HR: 3.22; p = 0.03) were significant predictors of the URFS.

conclusionsThis is the first study to show that specific KRAS and RYR2 mutations were associated with the URFS.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsMutationNeoplasm Recurrence, LocalProto-Oncogene Proteins p21(ras)AdultAgedAged, 80 and overFemaleHepatectomyHumansMaleMiddle AgedPrognosisRetrospective StudiesRiskKRAS protein, humanProto-Oncogene Proteins p21(ras)KRAS G12DMolecular profilingPrognostic factorResectable colorectal liver metastasisUnresectable relapse

Identifiers

PMID39083120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.